177 related articles for article (PubMed ID: 10883419)
1. A mass balance study to evaluate the biotransformation and excretion of [14C]-triamcinolone acetonide following oral administration.
Argenti D; Jensen BK; Hensel R; Bordeaux K; Schleimer R; Bickel C; Heald D
J Clin Pharmacol; 2000 Jul; 40(7):770-80. PubMed ID: 10883419
[TBL] [Abstract][Full Text] [Related]
2. Adrenal suppression with high doses of inhaled fluticasone propionate and triamcinolone acetonide in healthy volunteers.
Wilson AM; Clark DJ; McFarlane L; Lipworth BJ
Eur J Clin Pharmacol; 1997; 53(1):33-7. PubMed ID: 9349927
[TBL] [Abstract][Full Text] [Related]
3. Mass balance study of [14C] rabeprazole following oral administration in healthy subjects.
Setoyama T; Drijfhout WJ; van de Merbel NC; Humphries TJ; Hasegawa J
Int J Clin Pharmacol Ther; 2006 Nov; 44(11):557-65. PubMed ID: 17176622
[TBL] [Abstract][Full Text] [Related]
4. Elimination profile of triamcinolone hexacetonide and its metabolites in human urine and plasma after a single intra-articular administration.
Coll S; Matabosch X; Llorente-Onaindia J; Carbó ML; Pérez-Mañá C; Monfort N; Monfort J; Ventura R
Drug Test Anal; 2019 Nov; 11(11-12):1589-1600. PubMed ID: 31087549
[TBL] [Abstract][Full Text] [Related]
5. The metabolic fate of triamcinolone acetonide in laboratory animals.
Gordon S; Morrison J
Steroids; 1978; 32(1):25-35. PubMed ID: 100904
[TBL] [Abstract][Full Text] [Related]
6. Metabolism of triamcinolone acetonide-21-phosphate in dogs, monkeys, and rats.
Kripalani KJ; Cohen AI; Weliky I; Schreiber EC
J Pharm Sci; 1975 Aug; 64(8):1351-9. PubMed ID: 807712
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and pharmacodynamic evaluation of triamcinolone acetonide after intravenous, oral, and inhaled administration.
Rohatagi S; Hochhaus G; Mollmann H; Barth J; Galia E; Erdmann M; Sourgens H; Derendorf H
J Clin Pharmacol; 1995 Dec; 35(12):1187-93. PubMed ID: 8750370
[TBL] [Abstract][Full Text] [Related]
8. Absorption, distribution, metabolism, and excretion of N,N-diethyl-M-toluamide in the rat.
Schoenig GP; Hartnagel RE; Osimitz TG; Llanso S
Drug Metab Dispos; 1996 Feb; 24(2):156-63. PubMed ID: 8742226
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of triamcinolone acetonide after intravenous, oral, and inhaled administration.
Derendorf H; Hochhaus G; Rohatagi S; Möllmann H; Barth J; Sourgens H; Erdmann M
J Clin Pharmacol; 1995 Mar; 35(3):302-5. PubMed ID: 7608322
[TBL] [Abstract][Full Text] [Related]
10. A pharmacokinetic study to evaluate the absolute bioavailability of triamcinolone acetonide following inhalation administration.
Argenti D; Shah B; Heald D
J Clin Pharmacol; 1999 Jul; 39(7):695-702. PubMed ID: 10392324
[TBL] [Abstract][Full Text] [Related]
11. Percutaneous absorption of 14C-9alpha-fluoro-11beta,21-dihydroxy-3,20-dioxopregna-1,4-dieno (17alpha,16alpha-d)-2'-methyloxazolidine-21-acetate (L 6400) in rats, pigs and humans. Comparison with 3H-triamcinolone acetonide.
Lewis JD; Cameron BD; Hawkins DR; Chasseaud LF; Franklin ER
Arzneimittelforschung; 1975 Oct; 25(10):1646-50. PubMed ID: 54172
[TBL] [Abstract][Full Text] [Related]
12. Disposition and metabolism of 14C-rifapentine in healthy volunteers.
Reith K; Keung A; Toren PC; Cheng L; Eller MG; Weir SJ
Drug Metab Dispos; 1998 Aug; 26(8):732-8. PubMed ID: 9698286
[TBL] [Abstract][Full Text] [Related]
13. Metabolic disposition of [14C]bazedoxifene in healthy postmenopausal women.
Chandrasekaran A; McKeand WE; Sullivan P; DeMaio W; Stoltz R; Scatina J
Drug Metab Dispos; 2009 Jun; 37(6):1219-25. PubMed ID: 19273530
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, absorption, metabolism, and excretion of [
Prakash C; Fan B; Altaf S; Agresta S; Liu H; Yang H
Cancer Chemother Pharmacol; 2019 May; 83(5):837-848. PubMed ID: 30758648
[TBL] [Abstract][Full Text] [Related]
15. Nasal mucosal inflammation has no effect on the absorption of intranasal triamcinolone acetonide.
Argenti D; Colligon I; Heald D; Ziemniak J
J Clin Pharmacol; 1994 Aug; 34(8):854-8. PubMed ID: 7962675
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of pirazolac--a new anti-inflammatory drug--in human volunteers. I. Absorption, disposition, biotransformation and excretion.
Täuber U; Weiss C; Krause W; Acksteiner B; Matthes H
Eur J Drug Metab Pharmacokinet; 1985; 10(1):41-53. PubMed ID: 4029220
[TBL] [Abstract][Full Text] [Related]
17. Absorption, metabolism, and excretion of [14C]MK-0767 (2-methoxy-5-(2,4-dioxo-5-thiazolidinyl)-N-[[4-(trifluoromethyl)phenyl] methyl]benzamide) in humans.
Kochansky CJ; Rippley RK; Yan KX; Song H; Wallace MA; Dean D; Jones AN; Lasseter K; Schwartz J; Vincent SH; Franklin RB; Wagner J
Drug Metab Dispos; 2006 Sep; 34(9):1457-61. PubMed ID: 16772365
[TBL] [Abstract][Full Text] [Related]
18. Biotransformation of [
Pusalkar S; Plesescu M; Gupta N; Hanley M; Venkatakrishnan K; Wu JT; Xia C; Zhang X; Chowdhury S
Cancer Chemother Pharmacol; 2018 Nov; 82(5):803-814. PubMed ID: 30128949
[TBL] [Abstract][Full Text] [Related]
19. Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer.
Baker SD; Wirth M; Statkevich P; Reidenberg P; Alton K; Sartorius SE; Dugan M; Cutler D; Batra V; Grochow LB; Donehower RC; Rowinsky EK
Clin Cancer Res; 1999 Feb; 5(2):309-17. PubMed ID: 10037179
[TBL] [Abstract][Full Text] [Related]
20. Additional studies on triamcinolone acetonide use and misuse in sports: Elimination profile after intranasal and high-dose intramuscular administrations.
Coll S; Monfort N; Alechaga É; Matabosch X; Pérez-Mañá C; Ventura R
Steroids; 2019 Nov; 151():108464. PubMed ID: 31344406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
